Remimazolam

Generic Name: Remimazolam

Brand Names: Byfavo

Drug Type: Small Molecule

Chemical Formula: C_₂₁H_₁₉BrN_₄O_₂

CAS Number: 308242-62-8

Unique Ingredient Identifier: 7V4A8U16MB

Background: Remimazolam is an ultra short-acting benzodiazepine used in the induction and maintenance of sedation during short (<30 minute) procedures. Recent trends in anesthesia-related drug development have touted the benefits of so-called "soft drugs" - these agents, such as remifentanil, are designed to be metabolically fragile and thus susceptible to rapid biotransformation and elimination as inactive metabolites. These "soft drugs" are useful in the context of surgical procedures, wherein a rapid onset/offset is desirable, enabling anesthesiologists to manipulate drug concentrations as needed. Remimazolam was the first "soft" benzodiazepine analog to be developed and was approved for use by the FDA in July 2020 under the brand name Byfavo.

Indication: Remimazolam is indicated for the induction and maintenance of procedural sedation in adults undergoing procedures lasting 30 minutes or less.

Associated Conditions: Procedural Sedation

Clinical Trials

Clinical Studies of the Efficacy and Safety of Remimazolam for Anesthesia Induction and Maintenance in Elderly Patients

Phase 4

Not yet recruiting

Conditions: Efficacy and Safety

Interventions: Drug: Remimazolam
Drug: Propofol

First Posted Date: 2024-11-15

Last Posted Date: 2024-12-16

Lead Sponsor: Affiliated Hospital of Nantong University

Target Recruit Count: 60

Registration Number: NCT06690424

Comparison of Remimazolam and Etomidate As Induction Agents for Electroconvulsive Treatment

Phase 4

Completed

Conditions: Schizophenia Disorder
Major Depression Disorders
Schizoaffective Disorder
Bipolar

Interventions: Drug: Remimazolam
Drug: Etomidate

First Posted Date: 2024-10-29

Last Posted Date: 2024-10-31

Lead Sponsor: Yeongseok Yun

Target Recruit Count: 30

Registration Number: NCT06664138

Locations: 🇰🇷
Dankook University Hospital, Cheon-an, Korea, Republic of

Remimazolam Versus Midazolam for Sedation During Upper GI Endoscopy: a Randomized Controlled Trial

Phase 4

Recruiting

Conditions: Sedation for Diagnostic Gastroscopy

Interventions: Drug: Remimazolam
Drug: Midazolam

First Posted Date: 2024-09-26

Last Posted Date: 2024-12-04

Lead Sponsor: Koen Munters

Target Recruit Count: 148

Registration Number: NCT06614036

Locations: 🇳🇱
Gelre Hospitals, Apeldoorn, Gelderland, Netherlands
🇳🇱
Rijnstate hospital, Arnhem, Gelderland, Netherlands
🇳🇱
St Antonius hospital, Nieuwegein, Utrecht, Netherlands

Comparison of Remifentanil With a Combination of Remimazolam and Dexmedetomidine for Awake Tracheal Intubation

Not Applicable

Not yet recruiting

Conditions: Difficult or Failed Intubation
Sedative Adverse Reaction

Interventions: Drug: remimazolam combined with remifentanil
Drug: dexmedetomidine combined with remifentanil

First Posted Date: 2024-09-03

Last Posted Date: 2024-09-03

Lead Sponsor: Nanjing First Hospital, Nanjing Medical University

Target Recruit Count: 60

Registration Number: NCT06581731

Locations: 🇨🇳
Nanjing First Hospital, Nanjing, Jiangsu, China

Sedation Efficacy and Safety of Remazolam Besylate in Ventilated Surgical Critically Ill Patients

Phase 4

Recruiting

Conditions: Mechanical Ventilation Complication
Effect of Drug
Surgery
Critical Illness
Adverse Drug Event
Sedation

Interventions: Drug: Remimazolam Besylate
Drug: Dexmedetomidine Hydrochloride

First Posted Date: 2024-08-28

Last Posted Date: 2025-02-17

Lead Sponsor: Beijing Shijitan Hospital, Capital Medical University

Target Recruit Count: 306

Registration Number: NCT06575530

Locations: 🇨🇳
Beijing Shijitan Hospital.CMU, Beijing, Beijing, China

Effect of Remazolam on Hemodynamics During Hepatectomy

Phase 4

Completed

Conditions: Hemodynamic Instability

Interventions: Drug: Remimazolam
Drug: Propofol

First Posted Date: 2024-08-22

Last Posted Date: 2025-03-18

Lead Sponsor: Jun Zhang

Target Recruit Count: 70

Registration Number: NCT06565715

Locations: 🇨🇳
Fudan University Shanghai Cancer Center, Shanghai, China
🇨🇳
Fudan University Shanghai Cancer Center, Shanghai, China

Comparison of Efficacy and Safety Between Ciprofol and Remimazolam During Fiberoptic Bronchoscopy

Not Applicable

Not yet recruiting

Conditions: Fiberoptic Bronchoscopy

Interventions: Drug: Ciprofol
Drug: Remimazolam

First Posted Date: 2024-08-01

Last Posted Date: 2024-08-01

Lead Sponsor: Anhui Provincial Hospital

Target Recruit Count: 190

Registration Number: NCT06531915

Comparison of Remimazolam and Propofol on Emergence in Elderly Orthopedic Patients Under General Anesthesia

Phase 4

Completed

Conditions: Hip Fracture

Interventions: Drug: Propofol
Drug: Remimazolam
Drug: Flumazenil

First Posted Date: 2024-07-22

Last Posted Date: 2024-07-24

Lead Sponsor: Central South University

Target Recruit Count: 136

Registration Number: NCT06513923

Locations: 🇨🇳
Department of Anesthesiology, The Second Xiangya Hospital, Changsha, Hunan, China
🇨🇳
The Second Xiangya Hospital, Changsha, Hunan, China